uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results

uniQure (NASDAQ:QURE) posted its earnings results on Thursday. The biotechnology company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.08, reports. uniQure had a negative return on equity of 137.05% and a negative net margin of 1,027.52%. The firm had revenue of $11.13 million for the quarter, compared to analysts’ expectations of $3.47 million.

uniQure Stock Performance

Shares of NASDAQ:QURE traded down $0.17 on Friday, reaching $7.31. The company’s stock had a trading volume of 1,130,627 shares, compared to its average volume of 7,764,378. The stock’s 50-day moving average is $6.02 and its two-hundred day moving average is $5.53. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 9.39 and a quick ratio of 9.27. The stock has a market capitalization of $354.90 million, a P/E ratio of -1.18 and a beta of 0.97.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Raymond James & Associates raised its holdings in uniQure by 6.4% during the fourth quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 58.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 3,664 shares in the last quarter. Pale Fire Capital SE grew its position in uniQure by 9.2% during the fourth quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock worth $444,000 after buying an additional 5,500 shares during the period. Clear Harbor Asset Management LLC grew its position in uniQure by 35.2% during the second quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock worth $215,000 after buying an additional 12,500 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in uniQure during the fourth quarter worth about $86,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on QURE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, July 16th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a research report on Tuesday, July 9th. Mizuho cut their target price on uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 8th. Finally, The Goldman Sachs Group boosted their target price on uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.60.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.